Integer (NYSE:ITGR) Upgraded to Strong-Buy at Freedom Capital

Freedom Capital upgraded shares of Integer (NYSE:ITGR) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Several other brokerages have also recently commented on ITGR. Piper Sandler reissued an “overweight” rating and set a $97.00 target price (up from $87.00) on shares of Integer in a report on Friday, May 1st. Truist Financial increased their price target on Integer from $97.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. KeyCorp reiterated an “overweight” rating and set a $104.00 price target on shares of Integer in a research report on Tuesday. Finally, Zacks Research raised Integer from a “strong sell” rating to a “hold” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.00.

Integer Stock Up 0.2%

Integer stock opened at $96.46 on Wednesday. The stock has a market cap of $3.28 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 2.30 and a beta of 0.64. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. The company’s 50-day moving average price is $92.11 and its two-hundred day moving average price is $87.94. Integer has a 52 week low of $62.00 and a 52 week high of $116.31.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). The company had revenue of $439.58 million for the quarter, compared to the consensus estimate of $426.48 million. Integer had a return on equity of 12.83% and a net margin of 7.64%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, analysts expect that Integer will post 6.04 EPS for the current fiscal year.

Institutional Trading of Integer

Hedge funds and other institutional investors have recently made changes to their positions in the business. Salomon & Ludwin LLC boosted its holdings in Integer by 46.8% during the fourth quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 118 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Integer by 48.1% in the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 117 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Integer by 1,037.5% in the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 415 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Integer by 135.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 267 shares during the last quarter. Finally, Arax Advisory Partners lifted its position in shares of Integer by 2,489.5% during the 4th quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 473 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.